Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Screening System For Ocular Surface Malignant Tumors

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05645341Completed

Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface

NCT03515954CompletedPrimary

AS-OCT Guided Treatment of Diffuse CSCC

NCT00456495Phase 1CompletedPrimary

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Showing all 3 trials

Research Network

Common Treatments

  • Screening System For Ocular Surface Malignant Tumors1
  • Ranibizumab1
  • Treatment Of Diffuse Ocular Surface Squamous Neoplasia1

Active Sponsors

  • The New York Eye Cancer Center1
  • Benha University1
  • Genentech, Inc.1
  • Sun Yat-sen University1

Top Investigators

Related Conditions

  • Eye Neoplasms1
  • Orbital Neoplasms1

Activity Timeline